Home Cart Sign in  
Chemical Structure| 129425-81-6 Chemical Structure| 129425-81-6

Structure of MSA-2
CAS No.: 129425-81-6

Chemical Structure| 129425-81-6

MSA-2

CAS No.: 129425-81-6

MSA-2 is a STING agonist with anti-tumor activity that may be used in combination with anti-PD-1 therapy.

Synonyms: 5,6-dimethoxy-γ-oxo-benzo[b]thiophene-2-Butanoic Acid

4.5 *For Research Use Only !

Cat. No.: A1365634 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
25mg łËÇ˶ÊÊ Inquiry Inquiry
50mg ł§ÿî¶ÊÊ Inquiry Inquiry
100mg łÿóǶÊÊ Inquiry Inquiry
250mg łÇʧď¶ÊÊ Inquiry Inquiry
1g łËÿîʶÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 25mg

    łËÇ˶ÊÊ

  • 50mg

    ł§ÿî¶ÊÊ

  • 100mg

    łÿóǶÊÊ

  • 250mg

    łÇʧď¶ÊÊ

  • 1g

    łËÿîʶÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MSA-2

CAS No. :129425-81-6
Formula : C14H14O5S
M.W : 294.32
SMILES Code : O=C(O)CCC(C1=CC2=CC(OC)=C(OC)C=C2S1)=O
Synonyms :
5,6-dimethoxy-γ-oxo-benzo[b]thiophene-2-Butanoic Acid
MDL No. :MFCD32640674
InChI Key :APCLRHPWFCQIMG-UHFFFAOYSA-N
Pubchem ID :23035251

Safety of MSA-2

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages (BMDM) 0.01 mg/ml 1 day To assess the effect of MSA-2 on macrophage polarization, results showed MSA-2 significantly increased M1-like markers (CD86, H-2Kd) and proinflammatory cytokines (IFN-β, IL-6, TNF-α). PMC9548169
Bone marrow-derived dendritic cells (BMDC) 0.01 mg/ml 1 day To evaluate the effect of MSA-2 on STING pathway activation, results showed MSA-2 significantly upregulated DC maturation markers (CD80, CD86, H-2Kd, I-A/I-E) and proinflammatory cytokines (IFN-β, IL-6, TNF-α). PMC9548169
THP-1 cells 20 μM 1 hour Evaluate the activation effect of MSA-2 on the cGAS/STING signaling pathway in THP-1 cells PMC10916235
D2.0R cells 10-50 μM 16-48 hours To evaluate the effect of MSA-2 on NK cell killing of D2.0R cells, results showed MSA-2 significantly enhanced NK cell killing PMC11474167
Short-term expanded Vδ2 γδ T-cell lines 25 µM 24 h MSA-2 co-stimulated cytokine induction but induced cell death PMC8812774
Monocytes 25 µM 24 h MSA-2 stimulated IL-1β and TNF-α secretion and induced cell death PMC8812774
Vδ2 T cells 25 µM 24 h MSA-2 co-stimulated cytokine induction but inhibited proliferation PMC8812774
THP1 cells 40 μM 24 hours To validate STING activation by SAProsome-3 in THP1 cells, results showed upregulation of IFN-β, TNF-α, and CXCL10 mRNA expression and activation of STING downstream signaling. PMC10390568
Bone marrow-derived dendritic cells (BMDC) 40 μM 24 hours To evaluate the STING pathway activation by SAProsomes, results showed significant upregulation of IFN-β, TNF-α, and CXCL10 mRNA expression and promotion of DC maturation. PMC10390568
STING knockout PK-15 cells 30 μM 24 hours To verify whether the antiviral effect of MSA-2 depends on STING, results showed MSA-2 failed to inhibit SVV replication in STING knockout cells. PMC10675287
PK-15 cells 30 μM 24 hours To evaluate the inhibitory effect of MSA-2 on SVV replication, results showed MSA-2 significantly reduced viral RNA levels and virus titers. PMC10675287
RAW264.7 cells 10, 50 μM 24 hours Evaluate the effect of MSA-2 and MSA-2-Pt on the secretion of IFN-β by RAW264.7 cells. The results showed that both could trigger the secretion of IFN-β. PMC10795137
MC38 cells 25, 50, 75, 100, 200, 300 μM 24 hours Evaluate the effect of MSA-2 and MSA-2-Pt on the viability of MC38 cells. The results showed that MSA-2-Pt induced cell death significantly from 75 μM, showing a dose-dependent response, while MSA-2 did not cause cell death until 300 μM. PMC10795137
RAW264.7 cells 10, 25, 50 μM 3 hours Evaluate the activation of the STING signaling pathway by MSA-2 and MSA-2-Pt. The results showed that both MSA-2-Pt and MSA-2 increased the levels of phosphorylated P65 (P-P65). PMC10795137
Mouse bone marrow-derived dendritic cells 10 µM MSA-2 30 min pretreatment followed by 2h exposure to LLC-conditioned media To assess the effect of STING agonist MSA-2 on Ch25h mRNA expression, results showed MSA-2 partially prevented tumor-conditioned media-induced downregulation of Ch25h mRNA PMC9636202
MCF7 cells 35 μM 6 hours To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance. PMC11828882
A549 cells 35 μM 6 hours To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance. PMC11828882
CT26 cells 35 μM 6 hours To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance. PMC11828882
B16F10 cells 35 μM 6 hours To evaluate the activation of the STING-IFNβ pathway by MSA-2, results showed that MSA-2 significantly increased intracellular pIRF3 abundance. PMC11828882

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Metastatic dormancy model of breast cancer Intraperitoneal injection 1 mg per dose Single dose, 7 days post-inoculation To evaluate the effect of MSA-2 on breast cancer metastatic dormancy, results showed a single dose significantly prolonged mouse survival time PMC11474167
Mice Bilateral 4T1 tumor-bearing mice model Intravenous injection 10 mg/kg Single injection, observed for 21 days Evaluated the inhibitory effect of AMFL on primary and distant tumors, showing that AMFL+NIR treatment significantly suppressed primary tumor growth and controlled distant tumor growth, improving survival rates. PMC11887044
C57BL/6 mice MC38 colon carcinoma model and B16F10 melanoma model Intratumoral injection 150 μg Three doses Evaluate the antitumor effect of MSA-2-Pt in MC38 and B16F10 tumor models. The results showed that MSA-2-Pt significantly reduced tumor growth and increased survival, with 7/9 mice tumor-free in the MC38 model and 2/10 mice tumor-free in the B16F10 model. PMC10795137
BALB/c mice 4T1 breast cancer model Intravenous injection 2.4 mg/kg Every 2 days for a total of 3 times To evaluate the antitumor effect and immune activation of MSA-2 in vivo, results showed that MN NPs significantly inhibited tumor growth and promoted DC maturation and T-cell infiltration. PMC11223770
FVB mice EGFR-mutant lung cancer model Intraperitoneal injection 20 mg/kg Every three days Evaluate the effect of MSA-2 combined with osimertinib PMC9933873
C57BL/6 mice B16F10 tumor model Orthotopic implantation 22.5 mg/kg Single implantation, observed for 48 hours To evaluate the antitumor immune response of MSA-2 in vivo, results showed that MSA-2 significantly increased intratumor levels of IFNβ and IFNγ, and promoted DC maturation and T cell infiltration. PMC11828882
C57BL/6 mice Subcutaneous MC38 colorectal tumor model Intravenous injection 35 mg/kg Administered on days 0, 4, and 8, total of 3 doses To evaluate the antitumor efficacy of SAProsomes, results showed SAProsome-3 significantly inhibited tumor growth and induced 100% complete response rate. PMC10390568
Mice Subcutaneous LLC tumor model Oral 40 mg/kg MSA-2 orally, 5 mg/kg anti-PD-1 antibody i.p. Administered on day 4, 8, 12 and 16 To evaluate the anti-tumor efficacy of MSA-2 combined with anti-PD-1 therapy, results showed the combination significantly inhibited tumor growth and improved survival, which was dependent on CH25H expression PMC9636202
Mice B16, EMT-6, CT26, and H22 models Oral 50 mg/kg Single dose To evaluate the antitumor activity of MSA-2 combined with YM101, results showed the combination therapy significantly inhibited tumor growth and prolonged mouse survival. PMC9548169
Mice U14 and TC-1 cervical cancer models Oral 50 mg/kg Single dose To evaluate the inhibitory effect of MSA-2 alone or in combination with anti-PD-1 on the growth of subcutaneous cervical tumors. Results showed that MSA-2 significantly suppressed tumor growth and had a better effect when combined with anti-PD-1. PMC10972971
Mice B16F10 melanoma model Intratumoral injection 500 µg/dose Administered on days 1, 4, and 7 Evaluate the in vivo antitumor effect of DW18343, results showed DW18343 significantly inhibited tumor growth. PMC11661907
C57BL/6 mice Pan02 pancreatic cancer model Intravenous injection every 2 days for 16 days Every 2 days for 16 days Evaluate the in vivo antitumor activity of MSA-2 and cisplatin conjugates, showing significant tumor growth inhibition and enhanced immune response. PMC10852989

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.40mL

0.68mL

0.34mL

16.99mL

3.40mL

1.70mL

33.98mL

6.80mL

3.40mL

References

 

Historical Records

Categories